國家衛生研究院 NHRI:Item 3990099045/4394
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 859786      線上人數 : 830
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/4394


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4394


    題名: Comparative dosimetric evaluation of nanotargeted 188Re-(DXR)- liposome for internal radiotherapy
    作者: Chang, CH;Stabin, MG;Chang, YJ;Chen, LC;Chen, MH;Chang, TJ;Lee, TW;Ting, G
    貢獻者: National Institute of Cancer Research
    摘要: A dosimetric analysis was performed to evaluate nanoliposomes as carriers of radionuclides (Re-188-liposomes) and radiochemotherapeutic drugs [Re-188-doxorubicin (DXR)-liposomes] in internal radiotherapy for colon carcinoma, as evaluated in mice. Methods: Pharmacokinetic data for Re-188-N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA), Re-188-liposome, and Re-188-DXR-liposome were obtained for the estimation of absorbed doses in tumors and normal organs. Two colon carcinoma mouse models were employed: subcutaneous growing solid tumor and malignant ascites pervading tumor models. Radiation-dose estimates for normal tissues and tumors were calculated by using the OLINDA/EXM program. An evaluation of a recommended maximum administered activity (MAA) for the nanotargeted drugs was also made. Results: Mean absorbed closes derived from Re-188-liposome and Re-188-DXR-liposome in normal tissues were generally similar to those from Re-188-BMEDA in intraperitoneal and intravenous administration. Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively for Re-188-liposome and Re-188-DXR-liposome. Tumor-absorbed doses for the nanotargeted Re-188-liposome and Re-188-DXR-liposome were higher than those of Re-188-BMEDA for both routes of administration (4-26-fold). Dose to red marrow defined the recommended MAA. Conclusions: Our results suggest that radionuclide and chemoradiotherapeutic passive targeting delivery, using nanoliposomes as the carrier, is feasible and promising in systemic-targeted radionuclide therapy.
    日期: 2008-12
    關聯: Cancer Biotherapy and Radiopharmaceuticals. 2008 Dec;23(6):749-758.
    Link to: http://dx.doi.org/10.1089/cbr.2008.0489
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1084-9785&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000262772100009
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=56249130692
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    沒有與此文件相關的檔案.



    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋